Document is current
Any future updates will be listed below
-
Authors
de Santiago, Pamela R.
Sato, Sho https://orcid.org/0000-0001-5628-7141
Zhang, Stephanie J. https://orcid.org/0000-0001-6308-5257
Dougher, Meaghan C.
Devins, Kyle M.
Bilecz, Agnes J.
Rayamajhi, Sagar https://orcid.org/0000-0001-5420-7873
Mingo, Gabriel
Rendulich, Hannah S.
Feng, Yi
Wu, Connie https://orcid.org/0000-0002-4031-7286
Taylor, Martin S.
Zhuravlev, Yelena
Jung, Euihye
Omran, Dalia K.
Wang, Tian-Li
Shih, Ie-Ming
Schwartz, Lauren E.
Kim, Sarah
Morgan, Mark A.
Tanyi, Janos L.
Burns, Kathleen H.
Lengyel, Ernst
Parra-Herran, Carlos
Godwin, Andrew K. https://orcid.org/0000-0002-3987-9580
Walt, David R. https://orcid.org/0000-0002-5524-7348
Drapkin, Ronny https://orcid.org/0000-0002-6912-6977
- License Information
-
More Information
Article History
Received: 14 June 2024
Accepted: 24 February 2025
First Online: 6 March 2025
Competing interests
: D.R.W. has a financial interest in Quanterix Corporation, a company that develops an ultra-sensitive digital immunoassay platform. He is an inventor of the Simoa technology, a founder of the company, and also serves on its Board of Directors. D.R.W.’s interests were reviewed and are managed by Brigham and Women’s Hospital and Partners Healthcare in accordance with their conflict of interest policies. A.K.G. is a co-founder of Sinochips Diagnostics, serves as a scientific advisory board member to Biovica, Clara Biotech, EXOKĒRYX, VITRAC Therapeutics, and Sinochips Diagnostics, and receives research funding from Predicine and VITRAC Therapeutics. R.D. serves on the scientific advisory board of Repare Therapeutics. All other authors declare no financial or non-financial competing interests.
